((自动化翻译由路透提供，请见免责声明 ))
9月17日 - ** 经纪公司古根海姆将ANI Pharmaceuticals 的PT值从77美元上调至83美元，维持 "买入 "评级
** 新的PT较上一交易日收盘价上涨47.7
** 称，在完成对Alimera公司的收购后更新了模型
** 周一，ANIP宣布完成对Alimera Sciences 的收购，扩大了其罕见病业务。
** 券商预计，Alimera 24财年的产品收入为3440万美元，其中包括ANIP将记录的2024年第三季度最后两周的410万美元销售额。
** 称该交易将对 ANIP 的前景产生积极影响
** 5 家券商的平均评级相当于 "买入"；PT 中值为 83 美元
** 截至上次收盘，股价累计上涨 1.9
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.